PD1/PD-L1 inhibition may improve the antitumoral activity of R-MΦs and conversely, CSF1R inhibition may improve the effect of anti-PD1/PD-L1 monoclonal antibody in relapsed/refractory AML. This evidence concerns the gene PDCD1 and acute myeloid leukemia.